Mechanistic update of Trisenox in blood cancer

• Published in: Current research in pharmacology and drug discovery Vol. 5; p. 100166
• Main Authors: Ananta, Benerjee, Swati, Tchounwou, Paul B, Kumar, Sanjay
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier 2023
• Subjects: APL cells; PML-RARα; Trisenox; Trisenox; PML-RARα; APL cells
• ISSN: 2590-2571; 2590-2571
• DOI: 10.1016/j.crphar.2023.100166

Acute promyelocytic leukemia (APL)/blood cancer is M3 type of acute myeloid leukemia (AML) formed inside bone marrow through chromosomal translocation mutation usually between chromosome 15 & 17. It accounts around 10% cases of AML worldwide. Trisenox (TX/ATO) is used in chemotherapy for treatment of all age group of APL patients with highest efficacy and survival rate for longer period. High concentration of TX inhibits growth of APL cells by diverse mechanism however, it cures only PML-RARα fusion gene/oncogene containing APL patients. TX resistant APL patients (different oncogenic make up) have been reported from worldwide. This review summarizes updated mechanism of TX action via PML nuclear bodies formation, proteasomal degradation, autophagy, p53 activation, telomerase activity, heteromerization of pRb & E2F, and regulation of signaling mechanism in APL cells. We have also provided important information of combination therapy of TX with other molecules mechanism of action in acute leukemia cells. It provides updated information of TX action for researcher which may help finding new target for further research in APL pathophysiology or new TX resistant APL patients drug designing.